ATX-101 (deoxycholic acid injection) for reduction of submental fat. Issue 9 (1st September 2016)

• Record Type: Journal Article
• Authors: Ascher, Benjamin; Fellmann, Jere; Monheit, Gary
• Is Part Of: Expert review of clinical pharmacology. Volume 9:Issue 9(2016)
• Page Start: 1131
• Page End: 1143
• Publication Date: 2016-09-01
• Subjects: Adipocyte lysis -- ATX-101 -- deoxycholic acid -- efficacy -- facial esthetics -- injectable -- nonsurgical -- safety -- submental fat; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1080/17512433.2016.1215911
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Introduction : The shape and contour of the chin and neck play an important role in facial esthetics. As such, excess fat within the submental area (double chin) can negatively affect facial esthetics and body image. Common treatments for submental contouring include invasive procedures such as surgical rejuvenation and targeted liposuction. Energy devices (lasers, radiofrequency, and ultrasound) may be used to improve submental skin laxity while cryolipolysis was recently cleared in the United States for use in the submental area. However, ATX-101 (deoxycholic acid injection) is the only injectable drug approved in the United States and Canada for reduction of submental fat. Areas covered : The efficacy and safety of ATX-101 have been extensively evaluated in a global clinical development program including multiple Phase I/II studies and four large Phase III trials. Available data from ATX-101 trials are reviewed. Expert commentary : Injectables have been well established for facial rejuvenation. Extending injectable treatment into the chin and neck is a major advance for nonsurgical cosmetic correction. Overall, the evidence supports ATX-101 as a safe and effective, minimally invasive treatment alternative for reduction of submental fat that will provide a major tool for the esthetic physician.